Theravance Biopharma market cap is $1.3 b, and annual revenue was $60.37 m in FY 2018

Theravance Biopharma Revenue growth (FY, 2017 - FY, 2018), %292%

Theravance Biopharma Gross profit (FY, 2018)59.7 M

Theravance Biopharma Gross profit margin (FY, 2018), %98.8%

Theravance Biopharma Net income (FY, 2018)-215.5 M

Theravance Biopharma EBIT (FY, 2018)-238.8 M

Theravance Biopharma Cash, 31-Dec-2018378 M

Theravance Biopharma EV1.2 B

Theravance Biopharma revenue was $60.37 m in FY, 2018 which is a 292.4% year over year increase from the previous period.

Theravance Biopharma revenue breakdown by geographic segment: 18.4% from Europe, 81.6% from US and 0.0% from Other

USD | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Revenue | 48.6m | 15.4m | 60.4m |

| (68%) | 292% | |

## Cost of goods sold | 2.9m | 6.0m | 715.0k |

## Gross profit | 45.8m | 9.4m | 59.7m |

| 94% | 61% | 99% |

## R&D expense | 141.7m | 173.9m | 201.3m |

## General and administrative expense | 84.5m | 95.6m | 97.1m |

## Operating expense total | 226.2m | 269.5m | 298.4m |

## EBIT | (180.5m) | (260.1m) | (238.8m) |

| (371%) | (1691%) | (395%) |

## Interest expense | 1.4m | 8.5m | 10.5m |

## Pre tax profit | (180.6m) | (271.7m) | (226.1m) |

## Income tax expense | 10.1m | 13.7m | (10.6m) |

## Net Income | (190.7m) | (285.4m) | (215.5m) |

USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 18.4m | 5.5m | 19.1m | 3.1m | 3.5m | 4.3m | 8.3m | 23.5m | 12.8m |

## Cost of goods sold | 778.0k | 638.0k | 332.0k | 565.0k | 1.4m | 985.0k | 1.4m | 705.0k | |

## Gross profit | 17.6m | 4.8m | 18.7m | 2.5m | 2.1m | 3.3m | 22.0m | 12.1m | |

| 96% | 88% | 98% | 82% | 61% | 77% | 94% | 95% | |

## R&D expense | 35.7m | 32.1m | 32.0m | 40.6m | 42.9m | 39.3m | 47.8m | 48.6m | 52.7m |

## General and administrative expense | 23.6m | 20.3m | 20.3m | 20.8m | 24.3m | 20.9m | 24.7m | 25.0m | 21.9m |

## Operating expense total | 59.3m | 52.3m | 52.2m | 61.4m | 67.3m | 60.3m | 72.5m | 73.6m | 74.6m |

## EBIT | (41.6m) | (47.5m) | (33.5m) | (58.8m) | (65.1m) | (57.0m) | (65.0m) | (48.7m) | (62.4m) |

| (226%) | (868%) | (176%) | (1906%) | (1856%) | (1333%) | (781%) | (207%) | (486%) |

## Interest expense | 2.1m | 2.1m | 2.1m | 2.1m | 2.1m | 2.1m | |||

## Pre tax profit | (41.5m) | (47.2m) | (33.1m) | (59.9m) | (65.8m) | (66.0m) | (64.9m) | (47.6m) | (60.1m) |

## Income tax expense | 694.0k | 36.0k | 812.0k | 5.4m | 454.0k | 868.0k | 144.0k | (6.8m) | (659.0k) |

## Net Income | (42.1m) | (47.2m) | (34.0m) | (65.3m) | (66.3m) | (66.9m) | (65.1m) | (40.8m) | (59.4m) |

USD | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Cash | 344.7m | 89.0m | 378.0m |

## Accounts Receivable | 646.0k | 2.3m | 620.0k |

## Inventories | 12.2m | 16.8m | |

## Current Assets | 528.5m | 378.7m | 532.8m |

## PP&E | 8.5m | 10.2m | 13.2m |

## Total Assets | 639.3m | 441.4m | 560.2m |

## Accounts Payable | 1.7m | 5.9m | 9.0m |

## Current Liabilities | 49.3m | 62.6m | 98.6m |

## Long-term debt | 222.7m | 223.7m | 224.8m |

## Non-Current Liabilities | 239.8m | 263.7m | 513.3m |

## Total Debt | 222.7m | 223.7m | 224.8m |

## Common Stock | 1.0k | 1.0k | 1.0k |

## Additional Paid-in Capital | 862.7m | 913.7m | 960.7m |

## Retained Earnings | (512.2m) | (797.7m) | (1.0b) |

## Total Equity | 350.2m | 115.2m | (51.6m) |

## Debt to Equity Ratio | 0.6 x | 1.9 x | -4.4 x |

## Debt to Assets Ratio | 0.3 x | 0.5 x | 0.4 x |

## Financial Leverage | 1.8 x | 3.8 x | -10.9 x |

USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
---|---|---|---|---|---|---|---|---|---|

## Cash | 128.8m | 148.4m | 86.6m | 169.9m | 139.6m | 91.3m | 125.8m | 103.9m | 101.2m |

## Accounts Receivable | 1.5m | 1.9m | 873.0k | 1.2m | 1.3m | 1.6m | 2.0m | 3.4m | 3.0m |

## Inventories | 9.4m | 9.8m | 12.5m | 13.2m | 12.1m | 15.3m | 17.2m | 17.9m | 17.9m |

## Current Assets | 238.8m | 303.1m | 274.0m | 421.5m | 384.9m | 367.1m | 446.8m | 386.7m | 332.6m |

## PP&E | 10.1m | 8.8m | 8.8m | 8.3m | 8.7m | 8.6m | 10.3m | 10.7m | 12.4m |

## Total Assets | 293.1m | 374.5m | 356.3m | 588.0m | 543.9m | 486.2m | 480.1m | 421.4m | 371.0m |

## Accounts Payable | 9.1m | 7.4m | 5.4m | 3.6m | 6.4m | 5.6m | 5.1m | 3.6m | 3.7m |

## Current Liabilities | 46.4m | 44.7m | 45.4m | 49.0m | 57.1m | 48.8m | 105.2m | 93.5m | 102.0m |

## Long-term debt | 222.9m | 223.2m | 223.5m | 224.0m | 224.3m | 224.6m | |||

## Non-Current Liabilities | 8.2m | 8.2m | 13.0m | 245.1m | 245.7m | 251.3m | 311.5m | 293.5m | 282.4m |

## Total Debt | 222.9m | 223.2m | 223.5m | 224.0m | 224.3m | 224.6m | |||

## Common Stock | 1.0k | 1.0k | 1.0k | 1.0k | 1.0k | 1.0k | |||

## Additional Paid-in Capital | 602.1m | 732.3m | 742.7m | 871.9m | 885.3m | 895.2m | 926.0m | 937.4m | 948.8m |

## Retained Earnings | (363.7m) | (410.9m) | (444.9m) | (577.7m) | (643.9m) | (710.8m) | (861.7m) | (902.5m) | (962.0m) |

## Total Equity | 238.5m | 321.6m | 297.9m | 293.9m | 241.1m | 184.1m | 63.4m | 34.4m | (13.4m) |

## Debt to Equity Ratio | 0.8 x | 0.9 x | 1.2 x | 3.5 x | 6.5 x | -16.7 x | |||

## Debt to Assets Ratio | 0.4 x | 0.4 x | 0.5 x | 0.5 x | 0.5 x | 0.6 x | |||

## Financial Leverage | 1.2 x | 1.2 x | 1.2 x | 2 x | 2.3 x | 2.6 x | 7.6 x | 12.3 x | -27.6 x |

USD | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|

## Net Income | (190.7m) | (285.4m) | (215.5m) |

## Depreciation and Amortization | 3.1m | 4.0m | 3.2m |

## Accounts Receivable | 1.3m | (1.6m) | 1.6m |

## Inventories | (3.2m) | (7.3m) | (1.6m) |

## Accounts Payable | (16.4m) | 3.8m | 3.6m |

## Cash From Operating Activities | (99.0m) | (201.1m) | (112.9m) |

## Purchases of PP&E | (2.1m) | (2.4m) | (7.2m) |

## Cash From Investing Activities | (2.1m) | (2.4m) | (7.2m) |

## Cash From Financing Activities | 479.2m | 1.7m | 225.2m |

## Net Change in Cash | 232.0m | (255.7m) | 289.0m |

## Interest Paid | 7.5m | 7.5m |

USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (42.1m) | (89.4m) | (123.3m) | (65.3m) | (131.6m) | (198.5m) | (65.1m) | (105.9m) | (165.3m) |

## Depreciation and Amortization | 699.0k | 1.2m | 1.9m | 1.1m | 2.1m | 3.0m | 900.0k | 1.7m | 2.3m |

## Accounts Receivable | 395.0k | 66.0k | 1.0m | (587.0k) | (700.0k) | (930.0k) | 280.0k | (1.2m) | (771.0k) |

## Inventories | 134.0k | 157.0k | (1.8m) | 140.0k | (497.0k) | (3.0m) | (371.0k) | (351.0k) | (552.0k) |

## Accounts Payable | (9.4m) | (10.8m) | (12.8m) | 2.0m | 4.8m | 3.5m | (449.0k) | (2.3m) | (1.7m) |

## Cash From Operating Activities | (26.3m) | (58.4m) | (70.9m) | (50.0m) | (94.6m) | (156.8m) | 49.8m | (11.7m) | (60.7m) |

## Purchases of PP&E | (684.0k) | (1.3m) | (1.7m) | (587.0k) | (1.3m) | (2.2m) | (2.8m) | (3.9m) | (5.7m) |

## Cash From Investing Activities | 16.4m | (52.2m) | (102.0m) | (123.5m) | (112.3m) | (97.6m) | (11.3m) | 30.7m | 77.3m |

## Cash From Financing Activities | 26.0m | 146.3m | 146.8m | (1.2m) | 1.8m | 1.0m | (1.7m) | (4.1m) | (4.4m) |

## Net Change in Cash | 16.1m | 35.7m | (26.1m) | (174.8m) | (205.1m) | (253.4m) | 36.9m | 14.9m | 12.2m |

## Interest Paid | 3.7m | 3.7m | 3.7m | 3.7m |

USD | Y, 2018 |
---|---|

## EV/EBIT | -4.9 x |

## EV/CFO | -10.4 x |

## Debt/Equity | -4.4 x |

## Debt/Assets | 0.4 x |

## Financial Leverage | -10.9 x |